NSRX - Nasus Pharma Ltd. News

Sectors

NSRX

Nasus Pharma Ltd.

4.08

300 x 3.88

700 x 4.10

bid

ask

0.02

0.39%

500 @ 04:10 PM

4.08 +0.00 (0.00%)

Ytd	-55.37%
1y	-49.58%

3.87

day range

4.09

1.98

52 week range

9.50

Open	3.90	Prev Close	4.10	Low	3.87	High	4.09	Mkt Cap	47.83M
Vol	4.66K	Avg Vol	21.06K	EPS	-1.13	P/E	N/A	Forward P/E	N/A
Beta	N/A	Short Ratio	N/A	Inst. Own	N/A	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	N/A	50-d Avg	3.36	200-d Avg	4.44	1yr Est	0.00

NSRX News

globenewswire.com

Nasus Pharma Announces Transition of Chief Financial Officer

TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE American: NSRX) ("Nasus"

benzinga.com

Nasus Pharma H1 EPS $(0.54) Misses $(0.20) Estimate

Nasus Pharma (AMEX:NSRX) reported quarterly losses of $(0.54) per share which missed the analyst con

globenewswire.com

Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update

Appointed Pharma Industry Veteran Brendan O'Grady as Chief Executive Officer Company on Track to Ad

defenseworld.net

Nasus Pharma (NYSEAMERICAN:NSRX) Trading Up 9.7% – Here’s Why

Nasus Pharma Ltd. (NYSEAMERICAN:NSRX - Get Free Report)'s share price was up 9.7% during mid-day tra

benzinga.com

Nasus Pharma Appoints Brendan O'Grady As CEO, Succeeding Dan Teleman, Effective July 27

Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a

globenewswire.com

Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer

TEL AVIV, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus", "Nasus

globenewswire.com

Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum

TEL AVIV, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” o

benzinga.com

Nasus Pharma Announces NS003 Trial Demonstrates Preclinical Pharmacokinetic Profile Comparable To IV

Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage ph

globenewswire.com

Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intrana

Study Comparing Intranasal Powder Formulation of Ondansetron Demonstrates Comparable Pharmacokinetic

globenewswire.com

Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphy

TEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” o

globenewswire.com

Nasus Pharma to Participate in Upcoming Investor Conferences

TEL AVIV, Israel, May 01, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or

benzinga.com

12 Health Care Stocks Moving In Wednesday's Intraday Session

benzinga.com

12 Health Care Stocks Moving In Friday's After-Market Session

benzinga.com

Citizens Maintains Market Outperform on Nasus Pharma, Lowers Price Target to $18

Citizens analyst Jason N. Butler maintains Nasus Pharma (AMEX:NSRX) with a Market Outperform and

benzinga.com

Nasus Pharma Announces Phase 2 Results From NS002 Shows Improvements In Early Absorption Compared To

Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage p

globenewswire.com

Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results

Recent Phase 2 topline results demonstrate NS002's potential for best-in-class epinephrine delivery,

globenewswire.com

BriefCast Publishes Transcript: Nasus Pharma NS002 Phase 2 Positive Topline Results Webinar Transcri

In a call hosted recently, Nasus Pharma (NYSE:NSRX) presented strong positive topline results from i

benzinga.com

12 Health Care Stocks Moving In Thursday's Pre-Market Session

benzinga.com

What's Going On With Nasus Pharma Stock On Wednesday

The Phase 2 study results indicated that NS002 has the potential to exceed EpiPen performance, demon

benzinga.com

What's Going On With Nasus Pharma Stock On Wednesday

Nasus Pharma stock drops despite fast NS002 results beating EpiPen. Here's why shares are fallin

benzinga.com

12 Health Care Stocks Moving In Monday's After-Market Session

benzinga.com

12 Health Care Stocks Moving In Monday's Intraday Session

benzinga.com

Nasus Pharma Stock Hits 52-Week Low - Here's Why

Nasus Pharma (NSRX) hits a 52-week low despite positive Phase 2 data for its EpiPen rival. See why t

benzinga.com

Crude Oil Down 4%; Dollar Tree Earnings Top Views

benzinga.com

Dow Jumps Over 500 Points; NY Empire State Manufacturing Index Falls In March

US stocks rise, Nasdaq gains 100 pts. Dow up 1.14%, Nasdaq up 1.38%, S&P 500 up 1.24%. Financial

benzinga.com

12 Health Care Stocks Moving In Monday's Pre-Market Session

benzinga.com

Nasus Pharma's Topline Results From Phase 2 Study Of NS002 For Anaphylaxis Shows NS002 Achieved Sign

NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compare

globenewswire.com

Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Signifi

NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compare

benzinga.com

12 Health Care Stocks Moving In Monday's After-Market Session

benzinga.com

Nasus Pharma To Present Topline Analysis From Its Phase 2 Repeated Dose Clinical Study Of NS002

Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage p

globenewswire.com

Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and

TEL AVIV, March 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "

globenewswire.com

Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum

TEL AVIV, March 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "

benzinga.com

12 Health Care Stocks Moving In Friday's Intraday Session

globenewswire.com

Nasus Pharma to Participate in Upcoming Investor Conferences

TEL AVIV, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "C

globenewswire.com

Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epin

TEL AVIV, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "

globenewswire.com

Nasus Pharma Announces Closing of $15.0 Million Private Placement

TEL AVIV, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "C

globenewswire.com

Nasus Pharma Announces Pricing of $15.0 Million Private Placement

TEL AVIV, Israel, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" o

benzinga.com

Nasus Pharma Announces Interim Results From Phase 2 Clinical Study Of NS002, Investigational Intrana

Interim results indicate NS002 demonstrated significantly faster absorption and higher peak epinephr

benzinga.com

12 Health Care Stocks Moving In Friday's Intraday Session

benzinga.com

Citizens Initiates Coverage On Nasus Pharma with Market Outperform Rating, Announces Price Target of

Citizens analyst Jason Butler initiates coverage on Nasus Pharma (AMEX:NSRX) with a Market Outper

benzinga.com

Nasus Pharma Appoints Eyal Rubin As EVP And CFO

Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma", "Nasus" or the "Company"), a

benzinga.com

Nasus Pharma Initiates Phase 2 Clinical Study To Evaluate NS002 Investigational Intranasal Epinephri

Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage p

benzinga.com

Nasus Pharma Announces Health Canada Has Issued A No-Objection Letter Allowing The Company To Procee

Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage ph

benzinga.com

12 Health Care Stocks Moving In Friday's After-Market Session

benzinga.com

12 Health Care Stocks Moving In Tuesday's After-Market Session

benzinga.com

Laidlaw & Co. Initiates Coverage On Nasus Pharma with Buy Rating, Announces Price Target of $22

Laidlaw & Co. analyst Yale Jen initiates coverage on Nasus Pharma (AMEX:NSRX) with a Buy rati